Ascentage Pharma Group International (AAPG) Non-Current Deffered Revenue (2023 - 2024)

Generated on {Timestamp} © BusinessQuant.com

Generated on {Timestamp} Powered by

Historic Non-Current Deffered Revenue for Ascentage Pharma Group International (AAPG) over the last 2 years, with Q4 2024 value amounting to $34.6 million.

• Ascentage Pharma Group International's Non-Current Deffered Revenue fell 85.26% to $34.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $34.6 million, marking a year-over-year decrease of 85.26%. This contributed to the annual value of $34.0 million for FY2024, which is 423.37% down from last year.
• Per Ascentage Pharma Group International's latest filing, its Non-Current Deffered Revenue stood at $34.6 million for Q4 2024, which was down 85.26% from $34.9 million recorded in Q4 2023.
• Over the past 5 years, Ascentage Pharma Group International's Non-Current Deffered Revenue peaked at $34.9 million during Q4 2023, and registered a low of $34.6 million during Q4 2024.

Peer Comparison